Biomaterial Database

Adefovir dipivoxil. 2003

María Buti, and Rafael Esteban

Liver Unit, Hospital General Universitari Vall d' Hebron, Barcelona, Spain. mbuti@hg.vhebron.es

In chronic hepatitis B therapy there are new and exciting developments in antivirals such as nucleotide analogues. Adefovir is the latest drug approved for therapy of chronic hepatitis B. This agent has a potent in vitro and in vivo effect against herpes virus, retroviruses and hepadnaviruses. In the hepatitis B virus setting, adefovir dipivoxil inhibits both the wild type and HBV lamivudine-resistant strains. Adefovir is an oral drug and the recommended dose for chronic hepatitis B is 10 mg daily. The safety profile of this dose is excellent but higher doses can produce renal tubular damage, particularly when the drug is used for prolonged therapy. Up to now, no evidence of HBV resistance to adefovir dipivoxil has been detected, and this constitutes one of its main advantages as it permits longer duration of therapy. Adefovir is an important new addition to current first-line treatments for HBeAg and anti-HBe-positive chronic hepatitis B, as well as being rescue therapy for lamivudine-resistant HBV strains.

UI	MeSH Term	Description	Entries
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004347	Drug Interactions	The action of a drug that may affect the activity, metabolism, or toxicity of another drug.	Drug Interaction,Interaction, Drug,Interactions, Drug
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000225	Adenine	A purine base and a fundamental unit of ADENINE NUCLEOTIDES.	Vitamin B 4,4, Vitamin B,B 4, Vitamin
D000998	Antiviral Agents	Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.	Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019694	Hepatitis B, Chronic	INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	Chronic Hepatitis B,Chronic Hepatitis B Virus Infection,Hepatitis B Virus Infection, Chronic
D063065	Organophosphonates	Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P	Phosphonate,Phosphonates,Phosphonic Acid Esters,Acid Esters, Phosphonic,Esters, Phosphonic Acid